News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Zacks Investment Research Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Agenus is a clinical-stage immuno-oncology company focusing on its lead program, the BOT+BAL combination, for various solid tumors. The company is funding Phase 3 trials through an oversubscribed private placement in July 2026, aiming for commercialization and potential approvals. Despite strong recent stock performance …
Renaissance Technologies LLC has reduced its stake in Agenus Inc. (NASDAQ:AGEN) by 47.4% in the first quarter, selling 257,900 shares and now owning 285,646 shares valued at approximately $954,000. Institutional investors collectively hold 61.46% of Agenus. Despite mixed analyst ratings, the biotechnology company's shares …
Vistagen Therapeutics (VTGN) announced a non-dilutive financing of up to $100 million with HealthCare Royalty Partners. This agreement extends the company's financial runway into 2027, allowing it to advance its late-stage clinical programs. The initial $50 million will support the Phase 3 PALISADE-2 trial …
Vistagen Therapeutics reported a net loss of $13.0 million for Q1 2027, an improvement from the prior year, with revenue increasing to $1.5 million. Despite this, the company flagged substantial doubt about its ability to continue as a going concern due to high operating …
William Blair has reiterated its Hold rating for VistaGen Therapeutics (VTGN.US). The report from the investment firm indicates their continued neutral stance on the company's stock.
WuXi PharmaTech Healthcare Fund I L.P. and its indirect parent WuXi AppTec Co., Ltd. have filed an amended Schedule 13G, disclosing a 3.5% beneficial ownership in Adagene Inc. (ADAG). As of June 30, 2026, they collectively own 2,891,594 ordinary shares, held in the form …
This article announces that QIAGEN N.V. has received a notification from the AFM (the Netherlands Authority For the Financial Markets) regarding a voting rights announcement. Wellington Management Group LLP reported a transaction on August 12, 2026, indicating they hold 4.96% of the voting rights …
Chen Yu, through TCG Crossover funds, has reported a 6.7% warrant-based stake in Vistagen Therapeutics (VTGN) via an amended Schedule 13G/A filing. TCG Crossover I holds 1.8% and TCG Crossover II holds 5.1%, with Chen Yu being the sole managing member of both general …
Vistagen (VTGN) reported a narrower net loss of $13.0 million for Q1 FY2027, an improvement from $15.1 million in the prior-year quarter, largely due to increased revenue and reduced R&D and G&A expenses. While its lead drug fasedienol missed its primary endpoint in the …
Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Volkswagen (XTRA:VOW3) is back in focus after reports it will appoint outgoing Audi sales chief Marco Schubert to lead its US business, with a fresh push into …
Sharemaestro market context Price below Trend Line 52 weeks -28.9%(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …
RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 7.9% in Ultragenyx Pharmaceutical Inc., totaling 7,796,895 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, which are held by funds advised …
Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …
This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.
Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due …
* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Volkswagen sits in the spotlight after analysts trimmed the average price target from €109 to about €105, with individual updated targets clustering around €115 …
Sharemaestro market context Price below Trend Line 52 weeks -28.9%Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Qiagen (QGEN) has drawn fresh attention after surpassing its own sales and EPS outlook for Q2 2026 and reaffirming full year guidance, along with FDA …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%Ultragenyx Pharmaceutical Inc.'s average 12-month price target has been slightly reduced to $52 from $52.84 by 18 analysts. This new target implies a potential upside of approximately 97% based on the August 13th closing price. The consensus analyst rating remains a "Buy" from 19 …
Ultragenyx Pharmaceutical is awaiting two crucial FDA decisions that could significantly impact its stock price, potentially raising it from $27 to $32 per share. The decisions involve gene therapy DTX401 for glycogen storage disease type Ia, with an 80% approval chance, and UX111, with …
Ultragenyx Pharmaceutical (RARE) is considered undervalued with a "soft Buy" rating and a probability-weighted fair value of approximately $32 per share, against its current price near $27. The company is anticipating two crucial FDA decisions soon: one for DTX401 on August 23rd and another …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Volkswagen stock has put investors under pressure, with the share price down about 39.4% over the past five years even though the broader …
Sharemaestro market context Price below Trend Line 52 weeks -28.9%This article announces a manager's transaction at QIAGEN N.V. involving Eva Pisa, a member of the administrative or supervisory body. The transaction is a retroactive adjustment for a February 2026 net share settlement, withholding an additional 544 shares to cover related taxes, and is …
Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own outlook. For a …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a passive ownership stake in Ultragenyx Pharmaceutical Inc. They beneficially own 6,560,809 shares, which constitutes 6.66% of Ultragenyx’s common stock. The filing, a SCHEDULE 13G, indicates shared voting power over 6,398,809 shares …
Search by ticker symbol or company name and select a result to open its chart.